David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, which is expected to reach $7 billion in sales in 2014. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in multiple specialty areas: ophthalmics, medical aesthetics, medical dermatology, neurology, and urologics.
As Chairman of the Board and Chief Executive Officer of Allergan, Mr. Pyott has driven long-term growth and stockholder value through a sophisticated customer-centric business model focused on meeting and exceeding the expectations of physicians and delivering products that help improve the lives of patients. As a leader who is committed to scientific advancement, and as an innovator with a strong background in consumer marketing, Mr. Pyott recognized the potential of BOTOX® to be used for cosmetic and therapeutic purposes. Today, BOTOX® is one of the company’s most renowned products and is now recognized by regulatory authorities as an effective treatment for more than 27 different indications across approximately 88 countries. Under Mr. Pyott’s leadership, Allergan’s investment in Research & Development has increased from less than $100 million in 1998 to approximately $1 billion in 2013, and the company has created an industry-leading Research & Development pipeline with more than 180 product and indication approvals secured worldwide in 2013 alone.
With a keen emphasis on achieving category leading market positions, in March 2006, Allergan acquired Inamed Corp. for over $3 billion to create the world’s largest medical aesthetics company. In 2007, Allergan acquired Groupe Laboratories Cornéal in France, and in 2012, acquired SkinMedica, Inc., making Allergan the fastest growing company in the US physician dispensed topical aesthetics category. More recently, the company acquired MAP Pharmaceuticals for its inhaled migraine therapy technology and TARIS Biomedical's® lead program, LiRIS®, currently in Phase 2 trials for the treatment of interstitial cystitis/ bladder pain syndrome (IC/BPS).
In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. Mr. Pyott has also been recognized for his financial and leadership accomplishments by many prominent and well-respected business organizations. Mr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4), 2013 (ranked #26) and 2009 (ranked #50), and was recognized as the “#1 CEO in Specialty Pharmaceuticals” by Institutional Investor magazine in 2005, 2007, and the “Best CEO Healthcare – Pharmaceuticals” in 2012 and 2013. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology.
Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, working over 17 years in several positions in strategic planning, marketing and general management around the world.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.
Mr. Pyott is a member of the Board of Directors of Avery Dennison Corporation. He serves on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization. In addition, he is Vice Chairman of the Board of Trustees of Chapman University, President of the ICOFoundation and is on the Dean’s Advisory Board of The Paul Merage School of Business at the University of California Irvine.